F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
about
F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profileRealistic expectations of prepulse inhibition in translational models for schizophrenia research.Exploring the role of 5-HT1A receptors in the regulation of prepulse inhibition in mice: implications for cross-species comparisons.The effects of pramipexole on prepulse inhibition and locomotor activity in C57BL/6J miceF15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.Effects of prolonged treatment with memantine in the MRL model of CNS lupus.Cross-species assessments of motor and exploratory behavior related to bipolar disorder.Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.Optimisation of anti-psychotic therapeutics: a balancing act?Evaluation of the behavioral and pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in ratsSerotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins.Evaluation of the potential of antipsychotic agents to induce catalepsy in rats: assessment of a new, commercially available, semi-automated instrument.Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.Further evaluation of the tropane analogs of haloperidol.
P2860
Q24564964-F8A2E7F6-9945-443A-990B-23C7C61491F5Q24645703-D844A5EE-3DDF-4714-912D-6ACB4E5D5C80Q30444307-7CE6E9C8-C7A2-4D3F-ACF3-0847B5879912Q30476573-28A2007D-5A8E-461C-8521-82CC0B00F742Q30494674-89FFA3D5-3757-4DEC-92FE-386304866035Q30612050-94A0E768-435D-4C90-B301-8BFB9931E11EQ33976551-3E8CA753-E787-4D92-8C5B-E2F1CE9B714EQ34169978-C7C142D4-91DE-45B8-8B87-45E24CFF7B9FQ36052751-69295F15-2654-4FA6-B0DD-47F1B1AE7C7CQ36059043-761E3010-63FC-4207-9E9D-D7010AC82FE0Q38062443-A4AFBFA4-75B9-41C3-9726-D6D0B355D533Q38835759-042E042A-92F8-4F79-88A2-B0F74620748FQ41433244-4C89CC34-B999-4571-BA82-02899B78AA09Q42108082-ABBB2765-7F50-45DB-A5DB-EAD1FD106B59
P2860
F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
F15063, a compound with D2/D3 ...... tive symptoms of schizophrenia
@nl
F15063, a compound with D2/D3 ...... ive symptoms of schizophrenia.
@ast
F15063, a compound with D2/D3 ...... ive symptoms of schizophrenia.
@en
type
label
F15063, a compound with D2/D3 ...... tive symptoms of schizophrenia
@nl
F15063, a compound with D2/D3 ...... ive symptoms of schizophrenia.
@ast
F15063, a compound with D2/D3 ...... ive symptoms of schizophrenia.
@en
prefLabel
F15063, a compound with D2/D3 ...... tive symptoms of schizophrenia
@nl
F15063, a compound with D2/D3 ...... ive symptoms of schizophrenia.
@ast
F15063, a compound with D2/D3 ...... ive symptoms of schizophrenia.
@en
P2093
P2860
P356
P1476
F15063, a compound with D2/D3 ...... ive symptoms of schizophrenia.
@en
P2093
A L Auclair
A Newman-Tancredi
E Prinssen
F Colpaert
M S Kleven
R Depoortère
P2860
P304
P356
10.1038/SJ.BJP.0707159
P407
P577
2007-03-20T00:00:00Z